Adjuvant Axitinib Treatment of Renal Cancer: A Randomized Double-blind Phase 3 Study of Adjuvant Axitinib vs. Placebo in Subjects at High Risk of Recurrent RCC
The purpose of this trial is to determine if adjuvant therapy with axitinib will prevent or delay the recurrence of renal cell cancer after surgery to remove the primary tumor in high risk patients.
100 项与 SFJ Pharma Ltd. II 相关的临床结果
0 项与 SFJ Pharma Ltd. II 相关的专利(医药)
100 项与 SFJ Pharma Ltd. II 相关的药物交易
100 项与 SFJ Pharma Ltd. II 相关的转化医学